Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus. Part B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year following the first dose.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A Number of Participants With Treatment Emergent Adverse Events
Timeframe: 12 weeks (to Day 85)
Part B Number of Participants With Treatment Emergent Adverse Events
Timeframe: 12 weeks (to Day 85)